Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
J Neuroimmunol
    November 2025
  1. ISHIHARA K, Naito H, Sugimoto T, Nakamori M, et al
    Comparison of prednisolone monotherapy vs. tacrolimus combination in NMOSD: Efficacy, safety, and optimal therapeutic timing.
    J Neuroimmunol. 2025;408:578737.
    >> Share

    October 2025
  2. HOSHINA Y, Liu S, Wright MA, Delic A, et al
    Prolonged corticosteroid therapy and steroid-sparing maintenance immunotherapy lower relapse risk in pediatric and adult MOGAD.
    J Neuroimmunol. 2025;407:578709.
    >> Share

  3. MORAES BF, Sucupira JCL, Junior MGO, Leite GAPD, et al
    When gut and nerves collide: A case of Neuromyelitis Optica Spectrum disorder after golimumab for ulcerative colitis.
    J Neuroimmunol. 2025;407:578700.
    >> Share

  4. SEN S, Kurtuncu M, Demir S, Gunduz T, et al
    Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD).
    J Neuroimmunol. 2025;407:578686.
    >> Share

    September 2025
  5. MANN GS, Nandwani S, Jain N
    Microscopic Polyangiitis With a Twist: A Rare Case of CRAO and Brainstem Infarction.
    J Neuroimmunol. 2025;406:578685.
    >> Share

  6. ARLT FA, Majed M, Wu J, Zekeridou A, et al
    N-type voltage-gated calcium channel antibody testing lacks diagnostic value in Lambert-Eaton myasthenic syndrome.
    J Neuroimmunol. 2025;406:578681.
    >> Share

  7. ZHANG LJ, Qi Y, Sun CY, Yang L, et al
    Tumefactive demyelination as the first presentation of MOG ab-associated disease.
    J Neuroimmunol. 2025;406:578653.
    >> Share

  8. LIU A, Lucas MC, Kazerooni L, Yousuf MM, et al
    Reversal of profound cortical atrophy with immunotherapy in pediatric anti-NMDA receptor encephalitis.
    J Neuroimmunol. 2025;406:578649.
    >> Share

  9. IYENGAR ARS, Dunkley PR, Dickson PW
    Immunity in Parkinson's disease - the role of adaptive and auto-immune responses and gut-microbiome axis.
    J Neuroimmunol. 2025;409:578755.
    >> Share

  10. HANSEN MM, El Mahdaoui S, Hansen MB, Hvalkof VH, et al
    Mononuclear phagocytes in blood and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis: Untreated and treated with anti-CD20 therapy.
    J Neuroimmunol. 2025;409:578751.
    >> Share

  11. MARTINEZ-MEDINA S, Olivas-Dominguez ER, Romero-Armenta RN, Avalos-Arias A, et al
    PERM associated with thymic carcinoma with triple-autoantibody positivity: case report and literature review.
    J Neuroimmunol. 2025;409:578753.
    >> Share

    August 2025
  12. XU XN, Luo WJ, Li HN, Li X, et al
    Treatment strategy for myasthenia gravis with GAD65-IgG associated neurological disorders: A case report.
    J Neuroimmunol. 2025;409:578741.
    >> Share

  13. KIMURA A, Takekoshi A, Maekawa Y, Tanaka K, et al
    Serum neurofilament light chain as a prognostic biomarker of glial fibrillary acidic protein autoimmunity.
    J Neuroimmunol. 2025;408:578739.
    >> Share

  14. ZHAO M, Li J, Jin L, Luo Z, et al
    Next-generation approaches in autoimmune encephalitis diagnosis: A multi-omics perspective.
    J Neuroimmunol. 2025;408:578740.
    >> Share

  15. TANG Y, Wang H, Wang X, Yan Z, et al
    Characterizing the relationship between FLAIR hyper-rim lesions and paramagnetic rim lesions in multiple sclerosis.
    J Neuroimmunol. 2025;408:578738.
    >> Share

  16. TANAKA K, Uzawa A, Yasuda M, Onishi Y, et al
    Serum from patients with MuSK antibody-positive myasthenia gravis triggers transcriptomic changes leading to muscle atrophy and weakness in human myotube cells.
    J Neuroimmunol. 2025;408:578735.
    >> Share

  17. TOMIZAWA Y, Okada H, Miyachi M, Hoshino Y, et al
    Apathy in autoimmune GFAP Astrocytopathy: A case series and literature review.
    J Neuroimmunol. 2025;408:578733.
    >> Share

  18. HOSHINA Y, Smith TL, Mstat AD, Wong KH, et al
    An updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: Analysis, equipoise, and the urgent need for evidence over anecdote.
    J Neuroimmunol. 2025;405:578651.
    >> Share

  19. MIYAKE S, Katsura Y, Baba M, Tomizawa-Shinohara H, et al
    Anti-IL-6R antibody treatment changes microglial phenotype in AQP4 peptide-immunized mice, leading to suppression of myelitis severity.
    J Neuroimmunol. 2025;405:578644.
    >> Share

  20. IQBAL A, Mubarak B, Amar A, Mukhtar S, et al
    Association of interleukins 17A and 22 levels and their common genetic polymorphisms in Guillain Barre syndrome.
    J Neuroimmunol. 2025;408:578721.
    >> Share

  21. EL-WAHSH S, Ramanathan S, Reddel S
    Clinical utility of autoantibodies in the diagnosis and management of Myasthenia gravis.
    J Neuroimmunol. 2025;407:578718.
    >> Share

  22. FAN T, Jiang Y, Hu W, Xu W, et al
    Efficacy of FcRn antagonist efgartigimod in the treatment of Miller-Fisher/Guillain-Barre overlap syndrome: Two case reports.
    J Neuroimmunol. 2025;407:578712.
    >> Share

  23. BICIMVEREN MS, Ciftci SN, Alp G
    A rare cause of visual impairment in patients with multiple sclerosis: Uveitis.
    J Neuroimmunol. 2025;407:578714.
    >> Share

    July 2025
  24. YANG C, Jiang X, Cheng Z, Zheng C, et al
    Neuroprotective effects of Analgecine by modifying cholesterol metabolism in EAE mice model of multiple sclerosis.
    J Neuroimmunol. 2025;407:578704.
    >> Share

  25. SAXENA S, Zhirova A, Krishnan R, Healy B, et al
    SARS-CoV-2 spike antibody and T cell response in MS patients on high efficacy therapies post vaccine.
    J Neuroimmunol. 2025;407:578694.
    >> Share

  26. LAUTEN TH, Reed EC, Natour T, Pitts LJ, et al
    Beta adrenergic signaling as a therapeutic target for autoimmunity.
    J Neuroimmunol. 2025;407:578705.
    >> Share

  27. AKOWUAH PK, Botchway E, Owusu E, Ohene DA, et al
    Are corneal nerve and dendritic cell parameters assessed via corneal confocal microscopy good markers for multiple sclerosis? - A systematic review and meta-analysis.
    J Neuroimmunol. 2025;407:578697.
    >> Share

  28. GOMEZ FP, Bake S, Young CR, Sohrabji F, et al
    Therapeutic effects of estrogens on inflammatory demyelination in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2025;407:578698.
    >> Share

  29. KAUR G, Kumari P, Devi P, Swaminathan A, et al
    Gut dysbiosis influences the pathophysiology of multiple sclerosis: A case-control study from North India.
    J Neuroimmunol. 2025;407:578696.
    >> Share

  30. INOUE Y, Fujii T, Kashu KY, Watanabe M, et al
    Associations between serum levels of alpha-calcitonin gene-related peptide and clinical features of neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2025;404:578615.
    >> Share

  31. SANDWEISS AJ, Rosen J, Aduru C, Chandrasekar A, et al
    MOGAD optic neuritis after mild head/orbital trauma in six children.
    J Neuroimmunol. 2025;404:578605.
    >> Share

  32. JAHANSOOZ JR, Kameoka AM, Shibuya J, Abramowitz J, et al
    Recurrent anti-NMDA receptor encephalitis in first-trimester pregnancy with initially antibody-negative CSF.
    J Neuroimmunol. 2025;404:578602.
    >> Share

    June 2025
  33. WELSH NC, DiSano KD, Pike SC, Linzey M, et al
    Network analysis of intrathecally synthesized proteins to unravel mechanisms of disease course in multiple sclerosis.
    J Neuroimmunol. 2025;406:578678.
    >> Share

  34. NIBBER A, Wills B, Pettingill P, Fox H, et al
    Evolution and significance of neuronal surface autoantibodies after Japanese encephalitis.
    J Neuroimmunol. 2025;406:578671.
    >> Share

  35. WON J, Kim J, Qiao F, Singh AK, et al
    Therapeutic potential of S-nitrosoglutathione reductase inhibitor in B cell-driven experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2025;406:578673.
    >> Share

  36. NASEER MA, Hegazy M, El-Mehdawy KM, Ashraf H, et al
    Serum levels of tumor necrosis factor and TNFRSF1A gene polymorphisms in Egyptian multiple sclerosis patients: the influence on susceptibility and severity.
    J Neuroimmunol. 2025;406:578672.
    >> Share

  37. PEREIRA DA, Mariano M, Marcon N, Maia MM, et al
    A rare neuroendocrine presentation in pediatric anti-glutamic acid decarboxylase autoimmunity: Case report and literature review.
    J Neuroimmunol. 2025;406:578670.
    >> Share

  38. CAKAN M, Demirel E, Cimen B, Ozen NPA, et al
    Comparison of clinical features of aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein associated disorder (MOGAD), and double seronegative NMOSD - A single center experience.
    J Neuroimmunol. 2025;403:578591.
    >> Share

  39. ABBOUD H, Steingo B, Vargas D, Patel J, et al
    Satralizumab treatment in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case series.
    J Neuroimmunol. 2025;403:578585.
    >> Share

  40. ZIVOTIC I, Kolic I, Stefanovic M, Stefanovic NM, et al
    Association of TGFB1 and IFNB1 expression levels in peripheral blood mononuclear cells with multiple sclerosis with respect to proximal rs1800469 and rs2275888 eQTLs.
    J Neuroimmunol. 2025;406:578666.
    >> Share

  41. JOHNSON CB, Fehmi J, Rinaldi S
    The immunology and neuropathology of the autoimmune nodopathies.
    J Neuroimmunol. 2025;406:578665.
    >> Share

  42. SAGHARICHI M, Aalipour MA, Eghbal E, Javandoust Gharehbagh F, et al
    Autoimmune encephalitis and delayed diagnosis in common variable immunodeficiency: A case report and review of literature.
    J Neuroimmunol. 2025;406:578662.
    >> Share

    May 2025
  43. WEIGEL J, Appeltshauser L, Sommer C, Doppler K, et al
    Proprioceptive endings at muscle spindles as a possible target of autoantibodies.
    J Neuroimmunol. 2025;405:578648.
    >> Share

  44. YAO ZY
    Reflections on the influence of seasonal and environmental factors in myasthenia gravis.
    J Neuroimmunol. 2025;405:578645.
    >> Share

  45. MAKHARIA A, Agarwal A, Garg D, Garg A, et al
    The dilemma of demyelination: A case of Schilder's disease with insights from literature.
    J Neuroimmunol. 2025;402:578584.
    >> Share

  46. WANG Y, Huan X, Song J, Zhu X, et al
    Clinical outcome and peripheral CD4(+) T profile in impending myasthenic crisis: A prospective cohort study.
    J Neuroimmunol. 2025;402:578572.
    >> Share

    April 2025
  47. DEFFENBAUGH JL, Jung KJ, Murphy SP, Liu Y, et al
    Corrigendum to "Novel model of multiple sclerosis induced by EBV-like virus generate a unique B cell population" [Journal of Neuroimmunology volume 394 (2024) 578408].
    J Neuroimmunol. 2025;404:578625.
    >> Share

  48. ONISHI Y, Uzawa A, Yasuda M, Akamine H, et al
    Elevated serum levels of IL-10 family and IL-12 family cytokines in myasthenia gravis.
    J Neuroimmunol. 2025;404:578621.
    >> Share

  49. MASI F, Al Qudsi S, Visigalli D, Zardini E, et al
    Oligoclonal IgM band patterns in multiple sclerosis: A two-center study.
    J Neuroimmunol. 2025;404:578622.
    >> Share

  50. NAGAPPA M, Mondal S, Rajeevan S, Pradeepkumar B, et al
    Exploring the role of altered oxi-inflammasome activity in the immunobiology of inflammatory neuropathies.
    J Neuroimmunol. 2025;401:578556.
    >> Share

  51. LI Q, Liu B, Guan Y, Wang Y, et al
    Double filtration plasmapheresis in autoimmune gastritis with subacute combined degeneration of the spinal cord: A case report.
    J Neuroimmunol. 2025;403:578618.
    >> Share

  52. ZHARIKOV Y, Shitova A, Melnikova P, Voloshin I, et al
    Autoantibody-mediated disorders of the central and peripheral nervous system: Overview Infection.
    J Neuroimmunol. 2025;403:578616.
    >> Share

  53. EL MAHDAOUI S, Husted SR, Hansen MB, Cobanovic S, et al
    Corrigendum to "Cerebrospinal fluid soluble CD27 is associated with CD8+ T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis" [Journal of neuroimmunology vol. 381 (2023): 578128].
    J Neuroimmunol. 2025;403:578607.
    >> Share

  54. PETROU P, Kassis I, Levi Y, Yaghmour N, et al
    Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells (MSC-NG01).
    J Neuroimmunol. 2025;403:578613.
    >> Share

  55. TRAN GT, Bedi S, Rakesh P, Verma ND, et al
    Autoantigen and IL-2 activated CD4(+)CD25(+)T regulatory cells are induced to express CD8 and are autoantigen specific in inhibiting experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2025;404:578611.
    >> Share

  56. ZHANG Z, Wu J, Xu D, Zhao S, et al
    Clinical characteristics and immunotherapy efficacy in autoimmune-associated benign epilepsy with centrotemporal spikes: A prospective cohort study.
    J Neuroimmunol. 2025;404:578603.
    >> Share

  57. MARQUES RF, Pedrosa DA, Talim N, Lemos JC, et al
    Relapsing-remitting multiple sclerosis as a potential consequence of thalidomide treatment: A case report.
    J Neuroimmunol. 2025;404:578606.
    >> Share

  58. STAYKOVA M, Bruestle A
    Nitric oxide and experimental autoimmune encephalomyelitis review.
    J Neuroimmunol. 2025;404:578586.
    >> Share

    March 2025
  59. WANG Z, Du X, Wang Q, Zhang Y, et al
    Ofatumumab for the treatment of COVID-19-associated autoimmune encephalitis: A case report.
    J Neuroimmunol. 2025;403:578590.
    >> Share

  60. ZEYDAN B, Neyal N, Nathoo N, Rangachari M, et al
    Effects of androgen modifying therapies on disease activity in older men with multiple sclerosis.
    J Neuroimmunol. 2025;403:578589.
    >> Share

  61. CHUANG TY, LaBarre BA, Corbali O, Healy BC, et al
    Endocrine disrupting chemicals in early MS disease activity.
    J Neuroimmunol. 2025;400:578546.
    >> Share

    February 2025
  62. KHEDR EM, Hassan MM, Ezzeldeen MY, El-Kady MS, et al
    Motor symptoms at onset and manual dexterity predict cognitive impairment in drug-naive individuals with multiple sclerosis.
    J Neuroimmunol. 2025;401:578571.
    >> Share

  63. SHAHBAKHSH M, Jalousian F, Hosseini SH, Naser Moghadasi A, et al
    Toxocara canis-originated recombinant C-type lectin improves the disability scores of experimental autoimmune encephalomyelitis in murine in vivo models.
    J Neuroimmunol. 2025;402:578569.
    >> Share

  64. KUO PC, Zhao Z, Scofield BA, Paraiso HC, et al
    Benzoylacetonitrile as a novel anti-inflammatory compound on attenuating microglia and encephalitogenic T cell activation in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2025;401:578557.
    >> Share

  65. HE D, Zhou Y, Zhang Y, Zhang J, et al
    Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series.
    J Neuroimmunol. 2025;401:578558.
    >> Share

  66. GHOSH S, Bhaskar R, Singh KK, Sinha JK, et al
    Immunotherapy challenges and potential role of unclassified antibodies in complex autoimmune encephalitis.
    J Neuroimmunol. 2025;401:578555.
    >> Share

  67. LIU Y, Sun H, Xu Y, Xuan B, et al
    Identification and characteristics of a novel CD8alphaalpha T cell subset in a refractory myasthenia gravis patient.
    J Neuroimmunol. 2025;400:578551.
    >> Share

  68. ZHANG M, Zhu X, Yu L, Fang Z, et al
    Pediatric anti-CaValpha2delta autoimmune encephalitis: A case report and literature review.
    J Neuroimmunol. 2025;401:578550.
    >> Share

  69. YAN Z, Yang X, Lin B, Zhu Q, et al
    Brain network alteration was associated with 'no evidence of disease activity' status in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2025;400:578549.
    >> Share

  70. CULINA S, Commere PH, Turc E, Jouy A, et al
    MicroRNA signatures of CD4(+) T cell subsets in healthy and multiple sclerosis subjects determined by small RNA-sequencing.
    J Neuroimmunol. 2025;401:578531.
    >> Share

    January 2025
  71. RANDHAWA G, Mobarakabadi M, D'Mello C, Morch MT, et al
    Targeting extracellular matrix components to attenuate microglia neuroinflammation: A study of fibulin-2 and CSPGs in a model of multiple sclerosis.
    J Neuroimmunol. 2025;400:578533.
    >> Share

  72. FALK KK, Cabrera LA, Junker R, Leypoldt F, et al
    Serum NfL predicts outcome and secondary autoimmunity in herpes-simplex encephalitis.
    J Neuroimmunol. 2025;400:578528.
    >> Share

  73. ETEMADIFAR M, Aghili A, Shojaei S, Alaei SA, et al
    Balo concentric sclerosis, an emerging variant of multiple sclerosis: A case-series and literature review.
    J Neuroimmunol. 2025;400:578527.
    >> Share

  74. LI Y, Chen P, Huang X, Huang H, et al
    Corrigendum to "Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients" [Journal of Neuroimmunology. 2024 Nov 15:396:578464].
    J Neuroimmunol. 2025 Jan 16:578526. doi: 10.1016/j.jneuroim.2025.578526.
    >> Share

  75. VORASOOT N, Halfdanarson TR, Madigan NN, Dubey D, et al
    Pre-existing Lambert-Eaton Myasthenic Syndrome and Scleroderma in a Patient with Neuroendocrine Carcinoma Undergoing Immune Checkpoint Inhibitor Cancer Immunotherapy.
    J Neuroimmunol. 2025;398:578485.
    >> Share

  76. GULEC B, Everest E, Uygunoglu U
    Letter to the Editor Regarding "Spinocerebellar ataxia masquerading as multiple sclerosis, a case report".
    J Neuroimmunol. 2025;399:578523.
    >> Share

  77. FALSO S, Zara P, Marini S, Puci M, et al
    Seasonal variation in myasthenia gravis incidence.
    J Neuroimmunol. 2025;399:578524.
    >> Share

    December 2024
  78. GURSKI CJ, Hajiyeva Z, Veltri AJ, Fenton K, et al
    Corrigendum to "Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels are B cell depletion with Ocrelizumab" [J. Neuroimmunol. 339:578502 (2024)].
    J Neuroimmunol. 2024;399:578519.
    >> Share

  79. ITOH C, Swart G, St Louis E, Gandhi M, et al
    IgLON5 autoimmunity secondary to immune checkpoint inhibitor.
    J Neuroimmunol. 2024;399:578516.
    >> Share

  80. HERNANDEZ RUIZ JJ, Romero Malacara AMC, Lopez Mota LA, Perez Guzman MJ, et al
    Therapeutic development towards T follicular helper cells as a molecular target in myasthenia gravis disease.
    J Neuroimmunol. 2024;399:578503.
    >> Share

  81. LIANG Y, Huang J, Zhang X, Xu F, et al
    Quantitative assessment of thalamic damage and serum neurofilament light chain in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2024;399:578504.
    >> Share

  82. GILLIGAN M, O'Donnell L, Westbrook A, Tubridy N, et al
    A complex and severe encephalitis associated with four co-existing neuronal cell-surface autoantibodies.
    J Neuroimmunol. 2024;399:578501.
    >> Share

  83. GURSKI CJ, Hajiyeva Z, Veltri AJ, Fenton K, et al
    Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels after B cell depletion with Ocrelizumab.
    J Neuroimmunol. 2024;399:578502.
    >> Share

    November 2024
  84. OZKOSAR A, Oktelik FB, Gelmez MY, Ozturk Erden S, et al
    Retinoic acid modulates peripheral blood helper innate lymphoid cell composition in vitro in patients with multiple sclerosis.
    J Neuroimmunol. 2024;398:578489.
    >> Share

  85. KIM S, Lee S, Chung YH, Ju H, et al
    Myelin oligodendrocyte glycoprotein antibody-associated disease with histopathologic features of primary CNS angiitis without demyelination: Case report and literature review.
    J Neuroimmunol. 2024;396:578467.
    >> Share

  86. LAI R, Wu Z, Wang H, Feng L, et al
    Ofatumumab treatment for severe refractory anti-NMDAR encephalitis: A case series.
    J Neuroimmunol. 2024;396:578458.
    >> Share

    October 2024
  87. FAN Z, Li J, Zhang Y, Kang J, et al
    Kidney injury: An overlooked manifestation in autoimmune encephalitis.
    J Neuroimmunol. 2024;397:578472.
    >> Share

  88. YASUDA M, Uzawa A, Kuwabara S, Suzuki S, et al
    Corrigendum to "Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan" [Journal of Neuroimmunology 385 (2023) 578241].
    J Neuroimmunol. 2024;397:578465.
    >> Share

  89. CHENG X, Cui C, Shen S, Li Z, et al
    Probiotics-regulated lithocholic acid suppressed B-cell differentiation in neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2024;395:578422.
    >> Share

  90. HONG Y, Gao L, Huang SQ, Liu S, et al
    Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series.
    J Neuroimmunol. 2024;395:578431.
    >> Share

  91. LI Y, Chen P, Huang X, Huang H, et al
    Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients.
    J Neuroimmunol. 2024;396:578464.
    >> Share

    September 2024
  92. LIU Y, Yang CL, Zhao XL, Zhao YJ, et al
    Characteristics of anti-contactin1 antibody positive autoimmune nodopathies combined with membranous nephropathy.
    J Neuroimmunol. 2024;396:578460.
    >> Share

  93. BAI G, Bai Y, Guan H, Ren H, et al
    A case report of lymphoproliferative disease in brain following therapies with mycophenolate Mofetil and Fingolimod and literature review.
    J Neuroimmunol. 2024;394:578410.
    >> Share

  94. YASUDA M, Uzawa A, Onishi Y, Handa H, et al
    Elevated serum levels of C-terminal agrin fragment in acetylcholine receptor antibody-positive myasthenia gravis.
    J Neuroimmunol. 2024;396:578455.
    >> Share

  95. BAXTER L, Hopkins S, O'Connor KC, Pham MC, et al
    Fluorescence-detection size-exclusion chromatography specifically detects autoantibodies targeting the ganglionic acetylcholine receptor in patients with autoimmune autonomic ganglionopathy.
    J Neuroimmunol. 2024;396:578454.
    >> Share

  96. HUANG YF, Briggs CM, Gokhale S, Punga AR, et al
    Elevated C1s/C1-INH in serum and plasma of myasthenia gravis patients.
    J Neuroimmunol. 2024;396:578447.
    >> Share

  97. SAMIM MM, Mandal R, Joy J, Dhar D, et al
    Spectrum of Auto-antibodies in NMO and MOG Associated CNS Demyelination- The SANMAD Study.
    J Neuroimmunol. 2024;396:578446.
    >> Share

  98. XU Y, Wei Y, Shi Z, Yin F, et al
    Multimodal magnetic resonance longitudinal study on the deep gray matter in multiple sclerosis patients with teriflunomide.
    J Neuroimmunol. 2024;396:578445.
    >> Share

    August 2024
  99. ABOSEIF A, Amin M, Macaron G, Ontaneda D, et al
    Discordance of reported multiple sclerosis clinical course amongst patients and providers.
    J Neuroimmunol. 2024;395:578443.
    >> Share

  100. BILEK F, Ercan Z, Deniz G, Ozgul S, et al
    High-intensity intermittent exercise increases serum levels of chitinase 3-like protein-1 and matrix metalloproteinase-9 in persons with multiple sclerosis.
    J Neuroimmunol. 2024;395:578434.
    >> Share

  101. CHEN P, Chen J, Huang H, Liu W, et al
    Conventional dendritic cells are more activated in the hyperplastic Thymus of myasthenia gravis patients.
    J Neuroimmunol. 2024;395:578441.
    >> Share

  102. WRIGHT MA, Guasp M, Lachner C, Day GS, et al
    Authors' response to letter to the editor: Electroconvulsive therapy in N-methyl-d-aspartate receptor encephalitis.
    J Neuroimmunol. 2024;393:578405.
    >> Share

  103. KRIEGER S, Zarif M, Bumstead B, Buhse M, et al
    Evaluating the effect of dimethyl fumarate on subclinical biomarkers in a real-world patient cohort.
    J Neuroimmunol. 2024;393:578397.
    >> Share

  104. SHARMA M, Pal P, Gupta SK, Potdar MB, et al
    Microglial-mediated immune mechanisms in autoimmune uveitis: Elucidating pathogenic pathways and targeted therapeutics.
    J Neuroimmunol. 2024;395:578433.
    >> Share

  105. LEHIKOINEN J, Strandin T, Parantainen J, Nurmi K, et al
    Fibrinolysis associated proteins and lipopolysaccharide bioactivity in plasma and cerebrospinal fluid in multiple sclerosis.
    J Neuroimmunol. 2024;395:578432.
    >> Share

  106. YARIMI JM, Sandweiss AJ, Salazar KP, Massrey C, et al
    IT-DEX and B cell depletion in a child with anti-GAD 65 autoimmune encephalitis presenting as NORSE: A case report.
    J Neuroimmunol. 2024;395:578430.
    >> Share

  107. ETEMADIFAR M, Alaei SA, Sedaghat N, Ghandehari AH, et al
    TEMPORARY REMOVAL: Pure spinal multiple sclerosis: A case series of a possible new entity.
    J Neuroimmunol. 2024 Aug 8:578429. doi: 10.1016/j.jneuroim.2024.578429.
    >> Share

  108. TORTOSA-CARRERES J, Cubas-Nunez L, Piqueras M, Castillo-Villalba J, et al
    Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?
    J Neuroimmunol. 2024;394:578428.
    >> Share

    July 2024
  109. LI YJ, Zhang XY, Zhang WJ, Han YL, et al
    Proteomics analysis of immune response-related proteins in Guillain-Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
    J Neuroimmunol. 2024;394:578423.
    >> Share

  110. WUERCH EC, Mirzaei R, Yong VW
    Niacin produces an inconsistent treatment response in the EAE model of multiple sclerosis.
    J Neuroimmunol. 2024;394:578421.
    >> Share

  111. DEFFENBAUGH JL, Jung KJ, Murphy SP, Liu Y, et al
    Novel model of multiple sclerosis induced by EBV-like virus generates a unique B cell population.
    J Neuroimmunol. 2024;394:578408.
    >> Share

  112. YOKOTE H, Miyazaki Y, Fujimori J, Nishida Y, et al
    Characterization of Japanese multiple sclerosis patients with progression independent of relapse activity: A 2-year multicenter cohort study.
    J Neuroimmunol. 2024;394:578407.
    >> Share

  113. PEGAT A, Chanson JB, Lozeron P, Joubert B, et al
    Identification of rare variants in the FBXO38 gene of patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    J Neuroimmunol. 2024;392:578381.
    >> Share

  114. WRIGHT MA, Guasp M, Lachner C, Day GS, et al
    Electroconvulsive therapy in N-methyl-d-aspartate receptor encephalitis: A retrospective cohort and scoping review of literature.
    J Neuroimmunol. 2024;392:578369.
    >> Share

  115. FONSECA A, Santos E, Taipa R
    Balo concentric sclerosis: Literature review and report of two cases.
    J Neuroimmunol. 2024;392:578370.
    >> Share

    June 2024
  116. LI Y, Yi JS, Guptill JT, Juel VC, et al
    Immune dysregulation in chronic inflammatory demyelinating polyneuropathy.
    J Neuroimmunol. 2024;391:578360.
    >> Share

  117. RECHTMAN A, Zveik O, Haham N, Brill L, et al
    A protective effect of lower MHC-II expression in MOGAD.
    J Neuroimmunol. 2024;391:578351.
    >> Share

  118. WHEELER D, Bezih M, Lannen N
    Spinocerebellar ataxia masquerading as multiple sclerosis, a case report.
    J Neuroimmunol. 2024;393:578385.
    >> Share

  119. YONG HYF, Batty NJ, Tottenham I, Koch M, et al
    Soluble adhesion molecules: Cognitive worsening biomarkers in primary progressive multiple sclerosis?
    J Neuroimmunol. 2024;393:578384.
    >> Share

    May 2024
  120. SRIRAM S, Kim KW, Ljunggren-Rose A
    Targeted DeSUMOylation as a therapeutic strategy for multiple sclerosis.
    J Neuroimmunol. 2024;392:578371.
    >> Share

  121. GELIBTER S, Saraceno L, Pirro F, Susani EL, et al
    As time goes by: Treatment challenges in elderly people with multiple sclerosis.
    J Neuroimmunol. 2024;391:578368.
    >> Share

  122. CARVER JJ, Pugh BA, Lau KM, Didonna A, et al
    Lipid metabolism is dysregulated in endocrine glands upon autoimmune demyelination.
    J Neuroimmunol. 2024;391:578366.
    >> Share

    April 2024
  123. LI S, Sun D, Wang R, Du Q, et al
    Causal association between multiple sclerosis and severe COVID-19: A bidirectional Mendelian randomization study.
    J Neuroimmunol. 2024;391:578352.
    >> Share

  124. DAMMAN S, Sukpornchairak P, Ahituv A, Chen A, et al
    Unilateral cortical autoimmune encephalitis: A case series and comparison to late-onset Rasmussen's encephalitis.
    J Neuroimmunol. 2024;391:578350.
    >> Share

  125. MIN YG, Ju W, Sung JJ
    Superior oblique palsy as the initial manifestation of anti-contactin-1 IgG4 autoimmune nodopathy: A case report.
    J Neuroimmunol. 2024;391:578348.
    >> Share

  126. LI V, Binder MD, Purcell AW, Kilpatrick TJ, et al
    Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis.
    J Neuroimmunol. 2024;390:578347.
    >> Share

  127. MUNZ C
    Altered EBV specific immune control in multiple sclerosis.
    J Neuroimmunol. 2024;390:578343.
    >> Share

    March 2024
  128. LUO W, Wang X, Kong L, Chen H, et al
    Clinical features and prognosis of Tibetan patients with neuromyelitis optica spectrum disorder are different from those of Han Chinese patients.
    J Neuroimmunol. 2024;388:578263.
    >> Share

  129. KATSU M, Sekine-Tanaka M, Tanaka M, Horai Y, et al
    Inhibition of repulsive guidance molecule-a ameliorates compromised blood-spinal cord barrier integrity associated with neuromyelitis optica in rats.
    J Neuroimmunol. 2024;388:578297.
    >> Share

  130. HAHAM N, Zveik O, Rechtman A, Brill L, et al
    Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD.
    J Neuroimmunol. 2024;388:578289.
    >> Share

  131. DE ALMEIDA GMR, de Araujo RS, Castrillo BB, Silva GD, et al
    Therapeutic plasma exchange for neuromyelitis optica attacks: Evidence and challenges from a real-world cohort from Brazil.
    J Neuroimmunol. 2024;388:578295.
    >> Share

  132. CHANG EH, Hardy TA
    Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
    J Neuroimmunol. 2024;389:578330.
    >> Share

  133. FOGEL A, Olcer M, Goel A, Feng X, et al
    Novel biomarkers and interferon signature in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2024;389:578328.
    >> Share

    February 2024
  134. KMEZIC I, Press R, Glenewinkel H, Doppler K, et al
    Low-dose rituximab treatment in a patient with anti-neurofascin-155 IgG4 autoimmune nodopathy.
    J Neuroimmunol. 2024;389:578326.
    >> Share

  135. SRIWASTAVA S, Elkhooly M, Amatya S, Shrestha K, et al
    Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis.
    J Neuroimmunol. 2024;390:578315.
    >> Share

  136. ZHANG C, Liu R, Gao B, Li T, et al
    Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2024;387:578285.
    >> Share

  137. LOTFI A, Abbasi M, Karami N, Arghavanfar H, et al
    Effects of treadmill training on myelin proteomic markers and cerebellum morphology in a rat model of cuprizone-induced toxic demyelination.
    J Neuroimmunol. 2024;387:578286.
    >> Share

  138. SERAFINI B, Benincasa L, Rosicarelli B, Aloisi F, et al
    EBV infected cells in the multiple sclerosis brain express PD-L1: How the virus and its niche may escape immune surveillance.
    J Neuroimmunol. 2024;389:578314.
    >> Share

  139. FRID K, Usmann A, Markovits-Pachter T, Binyamin O, et al
    Granagard administration prolongs the survival of human mesenchymal stem cells transplanted into a mouse model of multiple sclerosis.
    J Neuroimmunol. 2024;389:578313.
    >> Share

  140. LI X, Chen JJ, Hur M, Paton GR, et al
    Papillitis associated with IgLON5 autoimmunity: A novel clinical phenotype.
    J Neuroimmunol. 2024;388:578312.
    >> Share

  141. TIAN J, Liu X, Liang H, Shen Y, et al
    Expression of lymphocyte activation gene-3 on CD4(+)T cells is regulated by cytokine interleukin-18 in myasthenia gravis.
    J Neuroimmunol. 2024;388:578308.
    >> Share

  142. GALETTA K, Ham AS, Vishnevetsky A, Bhattacharyya S, et al
    Disease modifying therapy in the treatment of tumefactive multiple sclerosis: A retrospective cohort study.
    J Neuroimmunol. 2024;388:578299.
    >> Share

    January 2024
  143. THAKOLWIBOON S, Linnoila J, Pittock SJ, Dubey D, et al
    Cerebellar leptomeningeal enhancement: An imaging finding of rapidly progressive Purkinje cell cytoplasmic autoantibody type 1 paraneoplastic cerebellar syndrome.
    J Neuroimmunol. 2024;387:578293.
    >> Share

  144. WADI L, Mandge V
    Electroconvulsive therapy for catatonia in anti-NMDA receptor encephalitis: A case series.
    J Neuroimmunol. 2024;386:578271.
    >> Share

  145. CERNE D, Losa M, Mattioli P, Lechiara A, et al
    Incident anti-LGI1 autoimmune encephalitis during dementia with Lewy bodies: when Occam razor is a double-edged sword.
    J Neuroimmunol. 2024;387:578291.
    >> Share

  146. PETERSEN-CHERUBINI CL, Liu Y, Deffenbaugh JL, Murphy SP, et al
    Dysregulated autotaxin expression by T cells in multiple sclerosis.
    J Neuroimmunol. 2024;387:578282.
    >> Share

  147. FUJIMORI J, Nakashima I
    Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis.
    J Neuroimmunol. 2024;387:578280.
    >> Share

    December 2023
  148. BAEVA ME, Tottenham I, Koch M, Camara-Lemarroy C, et al
    Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.
    J Neuroimmunol. 2023;387:578268.
    >> Share

  149. STAVROGIANNI K, Kitsos DK, Giannopapas V, Chasiotis AK, et al
    Neuropsychological profiles comparison between Multiple Sclerosis patients and Multiple Sclerosis patients with overlapping features of Systemic Lupus Erythematosus.
    J Neuroimmunol. 2023;387:578270.
    >> Share

  150. LI HY, Xia M, Song M, Xie Y, et al
    Rs1800629 polymorphism in TNF-alpha is associated with the susceptibility and initial short-term glucocorticoids efficacy in myasthenia gravis patients.
    J Neuroimmunol. 2023;387:578269.
    >> Share

  151. HU B, Dang G, Chen S, Li S, et al
    Neuromyelitis optica spectrum disorder mimicking stroke: A case report and literature review.
    J Neuroimmunol. 2023;385:578223.
    >> Share

  152. MIYAZAWA R, Fujimori J, Atobe Y, Nakashima I, et al
    CSF CXCL13 is elevated in patients with CIDP and may reflect higher disease activity.
    J Neuroimmunol. 2023;385:578238.
    >> Share

  153. TESFAGIORGIS Y, Kemal EA, Craig HC, Parham KA, et al
    Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed meninges in a chronic model of central nervous system autoimmunity.
    J Neuroimmunol. 2023 Dec 15:578267. doi: 10.1016/j.jneuroim.2023.578267.
    >> Share

    November 2023
  154. CHEN Y, Wan W, Yao X, Guan Y, et al
    Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection.
    J Neuroimmunol. 2023;385:578245.
    >> Share

  155. LOWE MC, Money KM, Matthews E, Pastula DM, et al
    case of autoimmune GFAP astrocytopathy with eosinophils in the cerebrospinal fluid.
    J Neuroimmunol. 2023;385:578249.
    >> Share

  156. CAO B, Li Q, Xiong L, Ruan H, et al
    Cerebrospinal fluid uric acid levels associated with disease severity in patients with anti-N-methyl-d-aspartate receptor encephalitis.
    J Neuroimmunol. 2023;384:578221.
    >> Share

  157. LI Y, Liu Y, Zhao W, An X, et al
    Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2023;384:578218.
    >> Share

  158. YASUDA M, Uzawa A, Kuwabara S, Suzuki S, et al
    Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan.
    J Neuroimmunol. 2023;385:578241.
    >> Share

  159. FARAJI J, Bettenson D, Yong VW, Metz GAS, et al
    Early life stress aggravates disease pathogenesis in mice with experimental autoimmune encephalomyelitis: Support for a two-hit hypothesis of multiple sclerosis etiology.
    J Neuroimmunol. 2023;385:578240.
    >> Share

    October 2023
  160. LEAL RATO M, Santos M, de Sa J, Ferreira J, et al
    Comorbid autoimmune disorders in people with multiple sclerosis: A retrospective cohort study.
    J Neuroimmunol. 2023;385:578226.
    >> Share

  161. MOORE L, Munir A, Bae S, Miller J, et al
    Transverse myelitis associated with Mpox infection.
    J Neuroimmunol. 2023;383:578190.
    >> Share

  162. KORAL G, Ulusoy C, Cossins J, Lazaridis K, et al
    Silencing of FCRLB by shRNA ameliorates MuSK-induced EAMG in mice.
    J Neuroimmunol. 2023;383:578195.
    >> Share

  163. RASHED HR, Niu Z, Dyck PJ, Dyck PJB, et al
    Nerve transcriptomes in autoimmune and genetic demyelinating neuropathies: Pathogenic pathway assessment of nerve demyelination.
    J Neuroimmunol. 2023;384:578220.
    >> Share

  164. KIM KW, Ljunggren-Rose A, Matta P, Toki S, et al
    Inhibition of SUMOylation promotes remyelination and reduces IL-17 mediated autoimmune inflammation: Novel approach toward treatment of inflammatory CNS demyelinating disease.
    J Neuroimmunol. 2023;384:578219.
    >> Share

    September 2023
  165. DOMINGUEZ L, McKeon A, Tobin WO, Lopez-Chiriboga S, et al
    Long term outcomes in patients with anti-DPPX autoimmunity.
    J Neuroimmunol. 2023;384:578214.
    >> Share

  166. HOLM-YILDIZ S, Dysgaard T, Krag T, Pedersen BS, et al
    Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis.
    J Neuroimmunol. 2023;384:578215.
    >> Share

  167. YASUDA M, Uzawa A, Ozawa Y, Kojima Y, et al
    Serum cytokine profiles in myasthenia gravis with anti-muscle-specific kinase antibodies.
    J Neuroimmunol. 2023;384:578205.
    >> Share

  168. CHENG X, Li Y, Wang Y, Sun Y, et al
    Impact of blood-brain barrier disruption on clinical features and treatment response in patients with newly diagnosed autoimmune encephalitis.
    J Neuroimmunol. 2023;383:578203.
    >> Share

  169. ROSHAN HM, Valadan R, Hosseini SA, Ajami A, et al
    Specific antibodies to EBNA1 epitopes as risk factors for multiple sclerosis, a systematic review.
    J Neuroimmunol. 2023;383:578202.
    >> Share

  170. CHHABRA S, Mehan S, Khan Z, Gupta GD, et al
    Matrine mediated neuroprotective potential in experimental multiple sclerosis: Evidence from CSF, blood markers, brain samples and in-silico investigations.
    J Neuroimmunol. 2023;384:578200.
    >> Share

  171. MICHAEL MR, Wieske L, Koel-Simmelink MJ, van Schaik IN, et al
    Serum B-cell activating factor is not a potential biomarker for disease activity in chronic inflammatory demyelinating polyneuropathy.
    J Neuroimmunol. 2023;382:578169.
    >> Share

  172. YAMAHARA N, Yoshikura N, Takekoshi A, Kimura A, et al
    Anti-N-methyl-d-aspartate receptor encephalitis preceded by meningitis lasting up to 60 days.
    J Neuroimmunol. 2023;382:578173.
    >> Share

  173. NI J, Liu X, Zhang R, Wang H, et al
    Systemic administration of Shikonin ameliorates cognitive impairment and neuron damage in NPSLE mice.
    J Neuroimmunol. 2023;382:578166.
    >> Share

  174. HUANG Z, Liu Y, An X, Zhang C, et al
    Rituximab induces a transient fluctuation of peripheral and follicular helper T cells in neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2023;382:578167.
    >> Share

  175. ERLEBACH R, Brandi G
    Effect and timing of operative treatment for teratoma associated N-Methyl-d-Aspartate receptor-antibody encephalitis: A systematic review with meta-analysis.
    J Neuroimmunol. 2023;382:578153.
    >> Share

  176. GELIBTER S, Pirro F, Saraceno L, Susani E, et al
    Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
    J Neuroimmunol. 2023;383:578199.
    >> Share

  177. PERDAENS O, van Pesch V
    MicroRNAs are dysregulated in peripheral blood mononuclear cells in multiple sclerosis and correlate with T cell mediators.
    J Neuroimmunol. 2023;386:578196.
    >> Share

    August 2023
  178. KHAN E, Kagzi Y, Elkhooly M, Surpur S, et al
    Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2023;383:578178.
    >> Share

  179. TERRIM S, Silva GD, de Sa E Benevides Falcao FC, Dos Reis Pereira C, et al
    Real-world application of the 2022 diagnostic criteria for first-ever episode of optic neuritis.
    J Neuroimmunol. 2023;381:578140.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016